NervGen Pharma Corp V.NGEN

Alternate Symbol(s): NGENF

Healthcare

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.

TSXV:NGEN - Post by User

NervGen Pharma Corp

<< Previous

Bullboard Posts

Next >>

Post by deepoil0808on Mar 26, 2024 11:44am

226 Views

Post# 35953096

Stock sharply down from $ 3.80/share (leaked results???)

Stock has dropped SHARPLY from $ 3.80 per share.

Sadly, shareholders are always the last to know. From reading the chart one would speculate that the trial results either are failing or are inconclusive, hence raising of cash + insider selling 33% of shares.

If results were great, then you raise at $ 30 per share after the results and not at $ 2.35 per share now.

We will know soon enough but it does not look promising.

My personal opinion,

Good Luck,

<< Previous

Bullboard Posts

Next >>

As AI expands, where can investors look for strong growth?